Back to top

Image: Bigstock

Zacks Investment Ideas feature highlights: Pfizer, Caterpillar, and Johnson & Johnson

Read MoreHide Full Article

For Immediate Release

Chicago, IL – August 8, 2022 – Today, Zacks Investment Ideas feature highlights Caterpillar (CAT - Free Report) , Johnson & Johnson (JNJ - Free Report) , and Pfizer (PFE - Free Report) .

3 Blue-Chip Stocks With Rock-Solid Dividends

Investing in blue-chip stocks is a stellar strategy. Blue-chip stocks are companies that have consistently provided quality, reliability, and the ability to operate profitably in both good and bad times.

Additionally, they generally carry robust dividend metrics – another major perk for investors.

Three companies that fit the parameters – Pfizer, Caterpillar, and Johnson & Johnson – would all be excellent selections for investors seeking a stream of income paired with solid growth prospects.

Let’s take a look at each company a little closer.


Caterpillar is the world’s largest construction-equipment manufacturer. The company designs, develops, engineers, manufactures, markets, and sells machinery, engines, financial products, and insurance to customers. The company is a Zacks Rank #3 (Hold) with an overall VGM Score of an A.

CAT has increased its dividend in 28 consecutive years, meeting the demanding requirements to join the elite Dividend Aristocrat group.

The company’s annual dividend yields 2.6%, with a payout ratio sitting sustainably at 41% of earnings. Additionally, the company has a notable 8.9% five-year annualized dividend growth rate. 

As it stands, CAT is projected to register substantial growth. For the current fiscal year (FY22), the Zacks Consensus EPS Estimate resides at $12.70, reflecting a stellar 18% year-over-year uptick.

The growth doesn’t stop there – CAT is forecasted to generate a mighty $57.5 billion in revenue in FY22, good enough for a double-digit 13% uptick from FY21 annual sales of $50.9 billion.

Johnson & Johnson

Johnson & Johnson is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods. The company is a Zacks Rank #3 (Hold) with an overall VGM Score of an A.

JNJ has increased its dividend for 60 consecutive years, making it not just a Dividend Aristocrat but a Dividend King as well – Dividend Kings have raised dividends for at least 50 straight years.

The company’s annual dividend yields 2.6%, with a payout ratio sitting sustainably at 45% of earnings. Additionally, the company has a five-year annualized dividend growth rate of a notable 6%. Johnson & Johnson’s yield is much higher than the S&P 500’s.

Of course, the titan is forecasted to grow at a solid pace – for the current fiscal year (FY22), earnings are expected to climb a respectable 3%.

Pivoting to top-line projections, the annual revenue estimate of $95 billion for FY22 pencils in a modest 1.5% year-over-year uptick.


Pfizer is a multinational pharmaceutical and biotechnology corporation headquartered in New York City, well-known for its COVID-19 vaccine. The company is a Zacks Rank #3 (Hold) with an overall VGM Score of an A.

Pfizer’s annual dividend yield sits enticingly at 3.2%, well above that of the S&P 500. In addition, the company’s payout ratio sits very sustainably at 26% of earnings, with an annualized five-year dividend growth rate of 4.7%.

The company has stellar growth projections. For the current fiscal year (FY22), the Zacks Consensus EPS Estimate resides at $6.54, reflecting a sizable 48% double-digit year-over-year uptick.

Top-line projections are rock-solid as well – PFE is forecasted to rake in $101.3 billion in revenue in FY22, a 25% year-over-year jump compared to FY21 annual sales of $81.5 billion.

Bottom Line

In addition to solid dividend payouts and consistent growth, blue-chip stocks are typically less volatile as well, another major perk for investors.

All three companies above had solidified themselves as titans in their respective industries.

In addition, all three companies have repeatedly reported quarterly results above expectations, and current fiscal year growth is inspiring.

For investors looking to add an additional layer of defense into their portfolio paired with solid growth and handsome dividend payouts, Caterpillar, Johnson & Johnson, and Pfizer would all fit those parameters.

Why Haven’t You Looked at Zacks' Top Stocks?

Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit information about the performance numbers displayed in this press release.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Caterpillar Inc. (CAT) - free report >>

Johnson & Johnson (JNJ) - free report >>

Pfizer Inc. (PFE) - free report >>

Published in